2565.HK
PEGBIO CO-B
HK$8.63
-2.27%
2026-05-29
About PEGBIO CO-B
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.
Key Fundamentals
EPS (TTM)
HK$-0.64
ROE
-82.4%
Profit Margin
0.0%
Debt/Equity
20.87
Price/Book
6.51
Market Cap
HK$3.38B
Avg Volume (10D)
29.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
HK$67.40
60D Low
HK$7.46
Avg Volume
5.8M
Latest Close
HK$8.63
Get breakout alerts for 2565.HK
Sign up for Breakout Scanner to receive daily notifications when 2565.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
PEGBIO CO-B (2565.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 2565.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 2565.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.